Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
30.33
+0.91 (3.11%)
Nov 9, 2026, 11:25 AM EST - Market open
Agios Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 140.84 | 54.03 | 36.5 | 26.82 | 14.24 | - | |
Revenue Growth | 214.44% | 48.03% | 36.07% | 88.36% | - | - |
Cost of Revenue | 352.16 | 345.88 | 305.45 | 298.41 | 281.61 | 256.97 |
Gross Profit | -211.32 | -291.85 | -268.95 | -271.58 | -267.37 | -256.97 |
Selling, General & Admin | 207.99 | 180.28 | 156.78 | 119.9 | 121.67 | 121.45 |
Operating Expenses | 207.99 | 180.28 | 156.78 | 119.9 | 121.67 | 121.45 |
Operating Income | -419.32 | -472.13 | -425.74 | -391.49 | -389.05 | -378.42 |
Interest & Investment Income | 41.82 | 56.38 | 48.08 | 33.34 | 12.79 | 0.84 |
Other Non Operating Income (Expenses) | 3.59 | 1.96 | 6.49 | 6.06 | 16.6 | 21.07 |
EBT Excluding Unusual Items | -373.91 | -413.8 | -371.17 | -352.09 | -359.65 | -356.51 |
Gain (Loss) on Sale of Assets | - | - | 200 | - | - | - |
Other Unusual Items | - | - | 889.14 | - | 127.85 | - |
Pretax Income | -373.91 | -413.8 | 717.97 | -352.09 | -231.8 | -356.51 |
Income Tax Expense | -1.02 | -1.02 | 44.24 | - | - | - |
Earnings From Continuing Operations | -372.9 | -412.78 | 673.73 | -352.09 | -231.8 | -356.51 |
Earnings From Discontinued Operations | - | - | - | - | - | 1,961 |
Net Income | -372.9 | -412.78 | 673.73 | -352.09 | -231.8 | 1,605 |
Net Income to Common | -372.9 | -412.78 | 673.73 | -352.09 | -231.8 | 1,605 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 59 | 58 | 57 | 56 | 55 | 60 |
Shares Outstanding (Diluted) | 59 | 58 | 58 | 56 | 55 | 60 |
Shares Change | 2.47% | 0.14% | 4.02% | 1.57% | -9.36% | -12.39% |
EPS (Basic) | -6.31 | -7.12 | 11.86 | -6.33 | -4.23 | 26.55 |
EPS (Diluted) | -6.31 | -7.12 | 11.64 | -6.33 | -4.23 | 26.55 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -335.97 | -377.29 | -391.53 | -297.06 | -314.36 | -413.06 |
Free Cash Flow Per Share | -5.69 | -6.51 | -6.76 | -5.34 | -5.74 | -6.83 |
Gross Margin | -150.04% | - | - | - | - | - |
Operating Margin | -297.72% | -873.87% | -1166.47% | -1459.52% | -2732.07% | - |
Profit Margin | -264.76% | -764.01% | 1845.92% | -1312.63% | -1627.82% | - |
Free Cash Flow Margin | -238.54% | -698.33% | -1072.73% | -1107.49% | -2207.58% | - |
EBITDA | -413.88 | -466.96 | -420.08 | -384.86 | -380.48 | -369.18 |
EBITDA Margin | -293.86% | - | - | - | - | - |
D&A For EBITDA | 5.43 | 5.18 | 5.65 | 6.62 | 8.56 | 9.24 |
EBIT | -419.32 | -472.13 | -425.74 | -391.49 | -389.05 | -378.42 |
EBIT Margin | -297.72% | - | - | - | - | - |
Effective Tax Rate | - | - | 6.16% | - | - | - |
Revenue as Reported | 140.84 | 54.03 | 36.5 | 26.82 | 14.24 | - |